Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Caso contributivo

PDF MeBrain

Il valproato tra terapia e tossicità tubulare: viaggio all'interno della sindrome di Fanconi

Valproate between therapy and tubular toxicity: journey inside Fanconi syndrome

Alice Ranieri1, Gina Pietrolati1, Enrico Perre1, Roberto Pillon2, Irene Alberici2, Andrea Pasini2
1Scuola di Specializzazione di Pediatria, Università di Bologna “Alma Mater Studiorum”
2SSD Nefrologia e Dialisi Pediatrica, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Gennaio 2026 | DOI: 10.53126/MEBXXIXG010

Abstract
Fanconi Syndrome (FS) is a proximal renal tubular dysfunction characterised by the urinary loss of normally reabsorbed substances. Although rare, it may occur as an iatrogenic complication of valproic acid (VPA) therapy in children. The paper reports the case of a 3-year-old boy (Trisomy 21, PEG-fed) treated with VPA for six months. The patient presented with dependent oedema and weight gain. Laboratory tests revealed significant proteinuria (PrU/CrU 5.9 mg/mg), glycosuria, alkaline urinary pH and reduced tubular reabsorption of phosphorus (TRP 64%). Blood tests confirmed metabolic acidosis, hypophosphataemia and hypouricaemia with preserved renal function. The clinical picture is consistent with VPA-induced acquired FS. The pathogenesis is linked to mitochondrial toxicity in the proximal tubule, driven by the inhibition of β-oxidation and depletion of carnitine and coenzyme A. Management involved the gradual discontinuation of VPA and enteral electrolyte supplementation and led to progressive metabolic recovery. This case highlights the necessity of monitoring tubular function in paediatric patients on long-term valproate therapy.
Riassunto
La sindrome di Fanconi è una disfunzione del tubulo prossimale caratterizzata da perdita urinaria di sostanze normalmente riassorbite. Sebbene rara, può manifestarsi come complicanza iatrogena della terapia con acido valproico in età pediatrica. Riportiamo il caso di un bambino di 3 anni (trisomia 21, alimentazione tramite PEG) in terapia con valproato da sei mesi. Il paziente presentava edemi declivi e aumento ponderale. Gli accertamenti hanno evidenziato proteinuria, glicosuria, pH urinario alcalino e ridotto riassorbimento di fosforo. Gli esami ematici hanno confermato acidosi metabolica, ipofosforemia e ipouricemia, con creatinina normale. Il quadro è compatibile con sindrome di Fanconi acquisita da valproato. La tossicità è legata al danno mitocondriale nel tubulo prossimale, indotto dall'inibizione della β-ossidazione e dalla deplezione di carnitina. Il trattamento ha previsto la sospensione graduale del valproato e la supplementazione elettrolitica, portando al progressivo compenso metabolico. Il caso sottolinea l'importanza di monitorare la funzione tubulare nei pazienti pediatrici in terapia cronica con valproato.
Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Roth KS, Foreman JW, Segal S. The Fanconi syndrome and mechanisms of tubular transport dysfunction. Kidney Int 198;20(6):705-16. DOI: 10.1038/ki.1981.200.
  2. Koda R, Itoh R, Tsuchida M, et al. Legionella Pneumonia Complicated with Acquired Fanconi Syndrome. Intern Med 2018;57(20):2975-80. DOI: 10.2169/internalmedicine.0942-18.
  3. Igarashi T. Pediatric Fanconi Syndrome. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, Em-ma F, Goldstein S, eds. Pediatric Nephrology. Springer 2014:1-40. DOI:10.1007/978-3-642-27843-3_38-1.
  4. Riccio E, Pisani A. Fanconi syndrome with lysinuric protein intolerance. Clin Kidney J 2014;7(6):599-601. DOI: 10.1093/ckj/sfu107.
  5. Curthoys NP, Moe OW. Proximal tubule function and response to acidosis. Clin J Am Soc Nephrol 2014;9(9):1627-38. DOI: 10.2215/CJN.10391012.
  6. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22(1):104-12. DOI: 10.1681/ASN.2010030246.
  7. Biber J, Hernando N, Forster I, Murer H. Regulation of phosphate transport in proximal tubules. Pflugers Arch 2009;458(1):39-52. DOI: 10.1007/s00424-008-0580-8.
  8. Ram R, Swarnalatha G, Ashok KK, Madhuri HR, Dakshinamurty KV. Fanconi syndrome following honeybee stings. Int Urol Nephrol 2012;44(1):315-8. DOI: 10.1007/s11255-010-9855-z.
  9. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys 2012 Jul 1;523(1):9-18. DOI: 10.1016/j.abb.2011.11.003.
  10. G. Bartolozzi. Fisiopatologia della vitamina D (Prima parte). Medico e Bambino pagine elettroniche 2007;10(9).
  11. Klootwijk E, Dufek S, Issler N, Bockenhauer D, Kleta, R. Pathophysiology, current treatments and future targets in hereditary forms of renal Fanconi syndrome. Expert Opinion on Orphan Drugs 2017; 5 (1):45-54. DOI: 10.1080/21678707.2017.1259560.
  12. Sinopoli HJ, Khouri Y. Failure to Thrive With Severe Hypokalemia Yields Cystinosis Diagnosis in a 19-Month-Old Female Child: A Case Report. Cureus 2024;16(6):e63122. DOI: 10.7759/cureus.63122.
  13. Fanconi G. Die nichtdiabetischen Glykosurien und Hyperglykämien des älteren Kindes. Jahrb Kinderheilkd 1931;133: 257 - 300.
  14. Bowden SA, Patel HP, Beebe A, McBride KL. Successful Medical Therapy for Hypophosphatemic Rickets due to Mitochondrial Complex I Deficiency Induced de Toni-Debré-Fanconi Syndrome. Case Rep Pediatr 2013;2013:354314. DOI: 10.1155/2013/354314.
  15. Rodriguez Soriano J, Houston IB, Boichis H, Edelmann CM Jr. Calcium and phosphorus metabolism in the fanconi syndrome. J Clin Endo-crinol Metab 1968;28(11):1555-63. DOI: 10.1210/jcem-28-11-1555.
  16. Imel EA. Congenital Conditions of Hypophosphatemia in Children. Calcif Tissue Int 2021;108(1):74-90. DOI: 10.1007/s00223-020-00692-5.
  17. Mallette LE, Patten BM. Neurogenic muscle atrophy and osteomalacia in adult Fanconi syndrome. Ann Neurol 1977;1(2):131-7. DOI: 10.1002/ana.410010205.
  18. Elkhateeb N, Selim R, Soliman NA, et al. Clinical and neurophysiological characterization of early neuromuscular involvement in children and adolescents with nephropathic cystinosis. Pediatr Nephrol 2022;37(7):1555-66. DOI: 10.1007/s00467-021-05343-x.
  19. Favarel-Garrigues M, Hentzien M, Berger JL, Brunet A, Bani-Sadr F. Life-threatening rhabdomyolysis and Fanconi syndrome related to tenofovir disoproxil fumarate administration in an HIV-infected patient. Med Mal Infect 2020;50(1):93-4. DOI: 10.1016/j.medmal.2019.08.003.
  20. Watanabe T. Proximal renal tubular dysfunction in primary distal renal tubular acidosis. Pediatr Nephrol 2005;20(1):86-8. DOI: 10.1007/s00467-004-1693-8.
  21. Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM 2014;107(4):261-9. DOI: 10.1093/qjmed/hct258.
  22. Gahl WA, Bernardini I, Dalakas M, et al. Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest 1988;81(2):549-60. DOI: 10.1172/JCI113353.
  23. Bernardini I, Rizzo WB, Dalakas M, Bernar J, Gahl WA. Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome. J Clin Invest 1985;75(4):1124-30. DOI: 10.1172/JCI111806.
  24. Filler G, Geda R, Salerno F, Zhang YC, de Ferris MED, McIntyre CW. Management of severe polyuria in idiopathic Fanconi syndrome. Pediatr Nephrol 2021;36(11):3621-6. DOI: 10.1007/s00467-021-05213-6.
  25. Usberti M, Pecoraro C, Federico S, et al. Mechanism of action of indomethacin in tubular defects. Pediatrics 1985;75(3):501-7.
  26. Kamperis K, Rittig S, Bower WF, Djurhuus JC. Effect of indomethacin on desmopressin resistant nocturnal polyuria and nocturnal enuresis. J Urol 2012;188(5):1915-22. DOI: 10.1016/j.juro.2012.07.019.
  27. AA.VV. Pediatric Nephrology - eight Edition. Springer Cham 2022.
  28. Wente-Schulz S, Aksenova M, Awan A, et al; international TIN study group. Aetiology, course and treatment of acute tubulointerstitial nephritis in paediatric patients: a cross-sectional web-based survey. BMJ Open 2021;11(5):e047059. DOI: 10.1136/bmjopen-2020-047059.
  29. Dreifuss FE, Langer DH. Side effects of valproate. Am J Med 1988;84(1A):34-41. DOI: 10.1016/0002-9343(88)90055-1.
  30. Wang C, Zhou Y, Song L, Deng Z, Fang W. Valproic-induced Fanconi syndrome: Clinical features, risk factors, diagnosis and management. Front Med (Lausanne) 2022;9:945244. DOI: 10.3389/fmed.2022.945244.
  31. Sturla Álvarez DA, Sánchez Marcos E, de Lucas Collantes C, Cantarín Extremera V, Soto Insuga V, Aparicio López C. Fanconi Syndrome Secondary to Sodium Valproate Therapy: Experience and Literature Review. Pediatr Neurol 2022;130:53-9. DOI: 10.1016/j.pediatrneurol.2022.03.001.
  32. Anguissola G, Leu D, Simonetti GD, Simonetti BG, Lava SAG, Milani GP, Bianchetti MG, Scoglio M. Kidney tubular injury induced by valproic acid: systematic literature review. Pediatr Nephrol 2023;38(6):1725-31. DOI: 10.1007/s00467-022-05869-8.
  33. Ramelli V, Ramelli GP, Lava SA, et al. Vitamin D status among children and adolescents on anti-convulsant drugs in southern Switzerland. Swiss Med Wkly 2014;144:w13996. DOI: 10.4414/smw.2014.13996.
  34. Haas RH, Parikh S, Falk MJ, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 2007;120(6):1326-33. DOI: 10.1542/peds.2007-0391.